SRR934744
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.680
- E2F_TARGETS+0.672
- MYC_TARGETS_V1+0.567
- MYC_TARGETS_V2+0.523
- MITOTIC_SPINDLE+0.490
- DNA_REPAIR+0.423
- TGF_BETA_SIGNALING+0.355
- UNFOLDED_PROTEIN_RESPONSE+0.342
- WNT_BETA_CATENIN_SIGNALING+0.292
- PROTEIN_SECRETION+0.239
Top 10 suppressed
- KRAS_SIGNALING_DN-0.409
- BILE_ACID_METABOLISM-0.351
- MYOGENESIS-0.351
- XENOBIOTIC_METABOLISM-0.330
- PANCREAS_BETA_CELLS-0.312
- INTERFERON_ALPHA_RESPONSE-0.297
- COAGULATION-0.295
- ESTROGEN_RESPONSE_LATE-0.262
- FATTY_ACID_METABOLISM-0.249
- INTERFERON_GAMMA_RESPONSE-0.238
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | D902E43A-F384-432A-B690-D20BFCC78443 | — | — | 0.953 |
| 2 | SRR934879 | — | — | 0.951 |
| 3 | SRR934937 | — | — | 0.944 |
| 4 | SRR934880 | — | — | 0.940 |
| 5 | C635C019-A66D-42B7-911C-4D0742CAF95A | — | — | 0.936 |
| 6 | SRR934990 | — | — | 0.935 |
| 7 | C6A16A8F-0AB7-42E9-A068-15EECF2912D3 | — | — | 0.934 |
| 8 | SRR934900 | — | — | 0.928 |
| 9 | DD5AA3F8-E3EE-4EDD-8152-B1CC07B70A08 | — | — | 0.924 |
| 10 | 4938761D-0762-4984-A399-BC036D6D2140 | — | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.680 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.672 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.567 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.523 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.490 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.423 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.355 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.342 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.292 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.239 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.177 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.117 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.099 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.024 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.004 | Remibrutinib | — uncovered |